Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 20761 AL 20775

GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment

Pal D, Mukherjee S, Song IH, Nimse SB.

Curr Drug Targets. 2021;22(15):1725-1737. doi: 10.2174/1389450122666210114095307.

Hyperhomocysteinemia and Dementia Associated With Severe Cortical Atrophy, but No Amyloid Burden

Reffo A, Gabelli C.

J Geriatr Psychiatry Neurol. 2022 Jan;35(1):57-61. doi: 10.1177/0891988720988910. Epub 2021 Jan 19.

Defining the Neuropathological Aggresome across in Silico, in Vitro, and ex Vivo Experiments

Gomes GN, Levine ZA.

J Phys Chem B. 2021 Mar 4;125(8):1974-1996. doi: 10.1021/acs.jpcb.0c09193. Epub 2021 Jan 19.

Deep Brain Stimulation in Alzheimer's Disease: Targeting the Nucleus Basalis of Meynert

Chen YS, Shu K, Kang HC.

J Alzheimers Dis. 2021;80(1):53-70. doi: 10.3233/JAD-201141.

Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders

Saha S, Pal D, Nimse SB.

Curr Drug Targets. 2021;22(12):1437-1462. doi: 10.2174/1389450122666210120143953.

Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities

Orad RI, Shiner T.

J Neurol. 2022 Feb;269(2):639-653. doi: 10.1007/s00415-021-10402-2. Epub 2021 Jan 29.

Editorial to the Special Issue "Lipidomics and Neurodegenerative Diseases"

Calvano CD, Losito I, Cataldi T.

Int J Mol Sci. 2021 Jan 28;22(3):1270. doi: 10.3390/ijms22031270.

A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer's and Parkinson's Disease

Lee JH, Kim HJ, Kim JU, Yook TH, Kim KH, Lee JY, Yang G.

Int J Mol Sci. 2021 Jan 28;22(3):1324. doi: 10.3390/ijms22031324.

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C.

Cochrane Database Syst Rev. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2.

An autopsy case of corticobasal syndrome due to asymmetric degeneration of the motor cortex and substantia nigra with TDP-43 proteinopathy, associated with Alzheimer's disease pathology

Tando S, Kasai T, Mizuta I, Takahashi H, Yaoi T, Saito K, Hojo T, Mizuno T, Hasegawa M, Itoh K.

Neuropathology. 2021 Jun;41(3):214-225. doi: 10.1111/neup.12723. Epub 2021 Feb 3.

Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases?

Ritchie DL, Barria MA.

Biomolecules. 2021 Feb 2;11(2):207. doi: 10.3390/biom11020207.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias

Cicognola C, Hansson O, Scheltens P, Kvartsberg H, Zetterberg H, Teunissen CE, Blennow K.

Alzheimers Res Ther. 2021 Feb 8;13(1):38. doi: 10.1186/s13195-020-00756-6.

Neuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases

Ben-Shushan S, Miller Y.

J Phys Chem B. 2021 Mar 25;125(11):2796-2811. doi: 10.1021/acs.jpcb.0c11151. Epub 2021 Feb 11.

The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: From antioxidant to epigenetic therapy

Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, Corpas R, Roig-Soriano J, Chillón M, Andres-Lacueva C, Somogyvári M, Sőti C, Sanfeliu C, Pallàs M.

Ageing Res Rev. 2021 May;67:101271. doi: 10.1016/j.arr.2021.101271. Epub 2021 Feb 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias